Analysts’ Weekly Ratings Changes for Avalo Therapeutics (AVTX)

A number of firms have modified their ratings and price targets on shares of Avalo Therapeutics (NASDAQ: AVTX) recently:

  • 11/7/2026 – Avalo Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/6/2026 – Avalo Therapeutics had its price target lowered by Wedbush from $22.00 to $20.00. They now have an “outperform” rating on the stock.
  • 11/4/2026 – Avalo Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/26/2026 – Avalo Therapeutics was given a new $16.00 price target by Oppenheimer.
  • 10/26/2026 – Avalo Therapeutics had its “outperform” rating reaffirmed by Oppenheimer.
  • 10/23/2026 – Avalo Therapeutics had its price target lowered by Wedbush from $34.00 to $22.00. They now have an “outperform” rating on the stock.
  • 10/23/2026 – Avalo Therapeutics had its price target lowered by BTIG Research to $10.00. They now have a “buy” rating on the stock.
  • 10/23/2026 – Avalo Therapeutics was downgraded by Guggenheim from “buy” to “neutral”.
  • 10/23/2026 – Avalo Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”.
  • 10/16/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by HC Wainwright.

Avalo Therapeutics Trading Down 5.2%

Shares of NASDAQ:AVTX traded down $0.41 during midday trading on Monday, reaching $7.36. The company had a trading volume of 1,116,528 shares, compared to its average volume of 1,340,667. The company’s 50 day moving average price is $12.33 and its 200 day moving average price is $15.64. The stock has a market cap of $425.29 million, a P/E ratio of -2.92 and a beta of 0.75. Avalo Therapeutics, Inc. has a 52-week low of $6.53 and a 52-week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.25. Research analysts forecast that Avalo Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $651,567. This represents a 23.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,258 shares of company stock valued at $395,434 in the last 90 days. 4.46% of the stock is owned by insiders.

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

Read More

Receive News & Ratings for Avalo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.